ArticleFrontiers in oncology2026
Analysis of
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although one-step nucleic acid amplification (OSNA), which measures cytokeratin (CK) 19 mRNA copies, is used for intraoperative detection of sentinel lymph node (SN) metastasis, CK19 mRNA copy number may not always accurately reflect total tumor load in the SN. Because number of DNA copies per cell generally has smaller deviation, we hypothesized that detection of tumor-derived mutated DNA in SNs, by targeting genetic mutations in the primary tumor, may provide more accurate results than OSNA. We investigated the Methods: We analyzed data from 94 patients who had undergone SN biopsy at Osaka University Hospital (April 2017 to March 2019). Next-generation sequencing was used for mutation analysis of the primary tumor. In cases of Results: Conclusions: Assessment of tumor-derived mutated DNA in SNs may be a useful technique to detect SN metastasis, as confirmed by ddPCR analysis. Further analyses, using data from a greater number of patients, are necessary to determine whether the results of whole-genome and whole-exome sequencing can be applied to other genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.